ABIVAX Société Anonyme (ABVX.PA)
EUR 7.48
(2.89%)
EUR 7.48
(2.89%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 327.06 Million EUR | 345.88% |
| 2022 | 73.35 Million EUR | -33.54% |
| 2021 | 110.36 Million EUR | 54.79% |
| 2020 | 71.29 Million EUR | 37.83% |
| 2019 | 51.72 Million EUR | -4.29% |
| 2018 | 54.04 Million EUR | 0.43% |
| 2017 | 53.81 Million EUR | -11.19% |
| 2016 | 60.59 Million EUR | -20.55% |
| 2015 | 76.26 Million EUR | 100.88% |
| 2014 | 37.96 Million EUR | -1.29% |
| 2013 | 38.46 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 284.49 Million EUR | 0.0% |
| 2023 Q2 | 171.1 Million EUR | 0.0% |
| 2023 FY | 327.06 Million EUR | 345.88% |
| 2023 Q4 | 327.06 Million EUR | 0.0% |
| 2022 Q4 | 73.35 Million EUR | 0.0% |
| 2022 Q2 | 71.64 Million EUR | 0.0% |
| 2022 FY | 73.35 Million EUR | -33.54% |
| 2021 FY | 110.36 Million EUR | 54.79% |
| 2021 Q4 | 110.36 Million EUR | 0.0% |
| 2021 Q2 | 55.09 Million EUR | 0.0% |
| 2020 Q4 | 71.29 Million EUR | 0.0% |
| 2020 Q2 | 49.81 Million EUR | 0.0% |
| 2020 FY | 71.29 Million EUR | 37.83% |
| 2019 FY | 51.72 Million EUR | -4.29% |
| 2019 Q2 | 54.59 Million EUR | 0.0% |
| 2019 Q4 | 51.72 Million EUR | 0.0% |
| 2018 Q2 | 46.04 Million EUR | 0.0% |
| 2018 FY | 54.04 Million EUR | 0.43% |
| 2018 Q4 | 54.04 Million EUR | 0.0% |
| 2017 Q2 | 55.18 Million EUR | 0.0% |
| 2017 FY | 53.81 Million EUR | -11.19% |
| 2017 Q4 | 53.81 Million EUR | 0.0% |
| 2016 Q4 | 60.59 Million EUR | 0.0% |
| 2016 Q2 | 66.66 Million EUR | 0.0% |
| 2016 FY | 60.59 Million EUR | -20.55% |
| 2015 Q2 | 89.35 Million EUR | 0.0% |
| 2015 Q4 | 76.26 Million EUR | 0.0% |
| 2015 FY | 76.26 Million EUR | 100.88% |
| 2014 Q3 | - EUR | 0.0% |
| 2014 FY | 37.96 Million EUR | -1.29% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 Q4 | 37.96 Million EUR | 0.0% |
| 2013 FY | 38.46 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -2123.399% |
| Adocia SA | 24.95 Million EUR | -1210.555% |
| Aelis Farma SA | 26.28 Million EUR | -1144.481% |
| Biophytis S.A. | 11.93 Million EUR | -2640.131% |
| Advicenne S.A. | 12.4 Million EUR | -2536.109% |
| genOway Société anonyme | 31.84 Million EUR | -927.128% |
| IntegraGen SA | 8 Million EUR | -3988.096% |
| Medesis Pharma S.A. | 1.92 Million EUR | -16878.459% |
| Neovacs S.A. | 47.53 Million EUR | -588.065% |
| NFL Biosciences SA | 3.97 Million EUR | -8137.035% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -2093.145% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -8629.17% |
| Sensorion SA | 46.49 Million EUR | -603.449% |
| Theranexus Société Anonyme | 7.23 Million EUR | -4418.843% |
| TME Pharma N.V. | 2.49 Million EUR | -13029.747% |
| Valbiotis SA | 33.24 Million EUR | -883.704% |
| TheraVet SA | 7.53 Million EUR | -4241.037% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -827.204% |
| argenx SE | 4.11 Billion EUR | 92.046% |
| BioSenic S.A. | 9.55 Million EUR | -3321.509% |
| Celyad Oncology SA | 16.28 Million EUR | -1908.734% |
| DBV Technologies S.A. | 165.65 Million USD | -97.441% |
| Galapagos NV | 4.35 Billion EUR | 92.494% |
| Genfit S.A. | 173.87 Million EUR | -88.105% |
| GeNeuro SA | 6.31 Million EUR | -5080.852% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | -585.938% |
| Innate Pharma S.A. | 184.19 Million EUR | -77.565% |
| Inventiva S.A. | 69.13 Million EUR | -373.05% |
| MaaT Pharma SA | 42.93 Million EUR | -661.832% |
| MedinCell S.A. | 36.94 Million EUR | -785.195% |
| Nanobiotix S.A. | 93.89 Million EUR | -248.32% |
| Onward Medical N.V. | 43.62 Million EUR | -649.644% |
| Oryzon Genomics S.A. | 106.9 Million EUR | -205.951% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | -299.343% |
| Oxurion NV | 6.55 Million EUR | -4893.313% |
| Pharming Group N.V. | 426.33 Million EUR | 23.286% |
| Poxel S.A. | 4.82 Million EUR | -6681.298% |
| GenSight Biologics S.A. | 9.08 Million EUR | -3499.23% |
| Transgene SA | 45.21 Million EUR | -623.316% |
| Financière de Tubize SA | 1.92 Billion EUR | 82.968% |
| UCB SA | 15.53 Billion EUR | 97.895% |
| Valneva SE | 469.39 Million EUR | 30.322% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -960.891% |